Artificial Intelligence Systems as Prognostic and Predictive Tools in Ovarian Cancer
暂无分享,去创建一个
[1] M. Friedlander,et al. The Role of Hormonal Therapy in Gynecological Cancers-Current Status and Future Directions , 2011, International Journal of Gynecologic Cancer.
[2] Satoshi Teramukai,et al. PIEPOC: a new prognostic index for advanced epithelial ovarian cancer--Japan Multinational Trial Organization OC01-01. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M. Brady,et al. Age as a prognostic factor in ovarian carcinoma: The gynecologic oncology group experience , 2010, Cancer.
[4] C. Tropé,et al. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. , 1995, Gynecologic oncology.
[5] D. Matei,et al. Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] R. Bristow. Predicting surgical outcome for advanced ovarian cancer, surgical standards of care, and the concept of kaizen. , 2009, Gynecologic oncology.
[7] ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of ovarian cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] J. Thigpen,et al. A Phase 3 Trial of Bevacizumab in Ovarian Cancer , 2012 .
[9] Paul Cross,et al. Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer. , 2012, Gynecologic oncology.
[10] C. Willmott,et al. Advantages of the mean absolute error (MAE) over the root mean square error (RMSE) in assessing average model performance , 2005 .
[11] Y. Drew,et al. Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors , 2010, Clinical Cancer Research.
[12] Björn Olsson,et al. Artificial intelligence techniques for bioinformatics. , 2002, Applied bioinformatics.
[13] Peter J. Selby,et al. Predicting Response to Bevacizumab in Ovarian Cancer: A Panel of Potential Biomarkers Informing Treatment Selection , 2013, Clinical Cancer Research.
[14] P. Harter,et al. The role of surgery in advanced and recurrent ovarian cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] E. Trimble,et al. Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis. , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] E. Høgdall. Cancer antigen 125 and prognosis , 2008, Current opinion in obstetrics & gynecology.
[17] J. Neijt,et al. Predictability of the survival of patients with advanced ovarian cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] John F Smyth,et al. Validation of a new prognostic index for advanced epithelial ovarian cancer: results from its application to a UK-based cohort. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] D. de Jong,et al. The prediction of progression‐free and overall survival in women with an advanced stage of epithelial ovarian carcinoma , 2009, BJOG : an international journal of obstetrics and gynaecology.
[20] H. Ngan,et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. , 2000, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[21] C. Robson,et al. Expression of gonadotrophin releasing hormone receptor I is a favorable prognostic factor in epithelial ovarian cancer. , 2008, Human pathology.
[22] R. Bristow,et al. Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer. , 2008, Gynecologic oncology.
[23] M F Jefferson,et al. Comparison of a genetic algorithm neural network with logistic regression for predicting outcome after surgery for patients with nonsmall cell lung carcinoma , 1997, Cancer.
[24] R. Herrmann,et al. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of pancreatic cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.